First-line treatment combining ibrutinib (Imbruvica, Pharmacyclics) and rituximab (Rituxan, Genentech) significantly improves progression-free survival (PFS) and overall survival compared with fludarabine, cyclophosphamide and rituximab (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL).
The PFS benefit was seen regardless of age, sex, performance status or disease stage, according to results from a randomized, phase 3 study presented at the American Society of